Compare Eli Lilly And Co (LLY) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Atlassian Corporation PLC — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Atlassian Corporation PLC trades at $206.79 (market cap $51.53B). The key difference: Eli Lilly And Co is far larger — about 20.2× Atlassian Corporation PLC's market cap, and Eli Lilly And Co pays a 0.59% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Atlassian Corporation PLC for 65 Days on average.
| LLY | TEAM | |
|---|---|---|
Market Cap | $1.04T | $51.53B |
Volume | 3,064,878 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $1.28K | $203.57 |
52-Week Low | $799.57 | $57.15 |
Typical Hold Time | 93 Days | 65 Days |
Enterprise Value | $1.09T | $51.52B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Atlassian (TEAM) trades at $203.57, up 4.04% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $5.22B in 2025 to projected $6.6B in 2026, though it remains unprofitable with a -0.82% net margin. Recent earnings beats and strong analyst sentiment (69.77% buy ratings) support the positive outlook, while the stock trades above the consensus price target of $191.16.
TEAM offers growth exposure to enterprise software and AI adoption, with cloud revenue up 31% and 95% subscription mix. However, high valuations (P/S 8.06, EV/EBITDA 242.85) and persistent losses create risk if growth slows. The stock faces resistance near $206-212 with RSI suggesting potential overbought conditions near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
